Inhibrx Biosciences (INBX) Interest Expenses (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Interest Expenses for 3 consecutive years, with $3.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Interest Expenses changed N/A year-over-year to $3.2 million; the TTM figure through Dec 2025 stood at $8.6 million (down 36.47% YoY), while the FY2025 annual figure was $220.3 million, up 911.25% from the prior year.
• Interest Expenses slipped to $3.2 million in Q4 2025 per INBX's latest filing, from $8.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $9.3 million in Q1 2025 and bottomed at $3.1 million in Q4 2023.
• Historically, Interest Expenses has averaged $6.9 million across 3 years, with a median of $8.0 million in 2025.
• Annual changes were most pronounced in 2024 — Interest Expenses plunged 31.69% — and 2025, when it surged 61.02%.
• Inhibrx Biosciences' Interest Expenses stood at $3.1 million in 2023, then surged by 73.24% to $5.4 million in 2024, then tumbled by 40.81% to $3.2 million in 2025.
• Business Quant data shows INBX's Interest Expenses at $3.2 million in Q4 2025, $8.0 million in Q3 2025, and $8.7 million in Q2 2025.